TY - JOUR
T1 - Patient preferences for attributes of injected or infused preventive migraine medications
T2 - Findings from a discrete choice experiment
AU - Schwedt, Todd J.
AU - Martin, Ashley
AU - Kymes, Steven
AU - Talon, Brian
AU - Lee, Xin Ying
AU - Cady, Roger
AU - Asher, Divya
AU - Karnik-Henry, Meghana
AU - Mulvihill, Emily
AU - Bates, Dawn
AU - Beusterien, Kathleen
N1 - Funding Information:
serves on the Board of Directors for the American Headache Society and the American Migraine Foundation. He has received research support from the American Migraine Foundation, Amgen, Henry Jackson Foundation, Mayo Clinic, National Institutes of Health, Patient‐Centered Outcomes Research Institute, and US Department of Defense. Within the past 12 months, he has received personal compensation for serving as a consultant or advisory board member for AbbVie, Axsome, Biodelivery Science, Collegium, Eli Lilly, Ipsen, Linpharma, Lundbeck, Novartis, and Satsuma. He holds stock options in Aural Analytics and Nocira. He has received royalties from UpToDate. , , , and are employees of Cerner Enviza (formerly Kantar Health), a company that received funding from Lundbeck LLC for time spent conducting this research. is an employee of H. Lundbeck A/S. , , , and are employees of Lundbeck LLC. was an employee of Lundbeck LLC at the time of study completion. Todd J. Schwedt Ashley Martin Emily Mulvihill Dawn Bates Kathleen Beusterien Xin Ying Lee Steven Kymes Brian Talon Divya Asher Meghana Karnik‐Henry Roger Cady
Publisher Copyright:
© 2023 The Authors. Headache: The Journal of Head and Face Pain published by Wiley Periodicals LLC on behalf of American Headache Society.
PY - 2023
Y1 - 2023
N2 - Objective: To assess preferences among adults with migraine for differentiating attributes of injected or infused preventive treatment options and evaluate their importance in determining a treatment choice. Background: Adults with migraine and health-care providers consider many factors when making treatment decisions. Injected or infused preventive migraine treatment options differ in several attributes, including mode of administration and dosing frequency, which may be preferentially selected or avoided by patients. Understanding a patient's preference is important for clinicians as they advise on various treatment options. Methods: A total of 604 US adults diagnosed with migraine participated in an online survey that captured information on demographics, migraine history, and treatment preferences. A discrete choice experiment (DCE) was used to evaluate participants’ preferences for specific attributes of injected/infused preventive migraine therapies. The DCE data were utilized to estimate attribute importance (expressed as a percentage) and identify subgroups that had different distributions of preferences. Results: In the overall migraine population, mode of administration (28.8%), durability of effectiveness (27.0%), and speed of onset (25.5%) had the highest relative importance, whereas administration setting (9.9%) and dosing frequency (8.8%) had the lowest. Four distinct subgroups were identified: Group 1 (n = 128) preferred self-injection administration and durability of effectiveness; Group 2 (n = 189) expressed aversion to cranial injections; Group 3 (n = 158) prioritized rapid speed of onset; and Group 4 (n = 129) favored health-care provider administration and durability of effectiveness. Conclusions: Speed of onset, durability of effectiveness, and mode of administration are key moderators of treatment preference among US adults with migraine. Certain segments of the migraine population prioritize specific treatment attributes over others, with intravenous infusion not considered a barrier in three of four identified segments. Clinicians can best help their patients find the right medication if they understand which medication attributes are most and least important to them.
AB - Objective: To assess preferences among adults with migraine for differentiating attributes of injected or infused preventive treatment options and evaluate their importance in determining a treatment choice. Background: Adults with migraine and health-care providers consider many factors when making treatment decisions. Injected or infused preventive migraine treatment options differ in several attributes, including mode of administration and dosing frequency, which may be preferentially selected or avoided by patients. Understanding a patient's preference is important for clinicians as they advise on various treatment options. Methods: A total of 604 US adults diagnosed with migraine participated in an online survey that captured information on demographics, migraine history, and treatment preferences. A discrete choice experiment (DCE) was used to evaluate participants’ preferences for specific attributes of injected/infused preventive migraine therapies. The DCE data were utilized to estimate attribute importance (expressed as a percentage) and identify subgroups that had different distributions of preferences. Results: In the overall migraine population, mode of administration (28.8%), durability of effectiveness (27.0%), and speed of onset (25.5%) had the highest relative importance, whereas administration setting (9.9%) and dosing frequency (8.8%) had the lowest. Four distinct subgroups were identified: Group 1 (n = 128) preferred self-injection administration and durability of effectiveness; Group 2 (n = 189) expressed aversion to cranial injections; Group 3 (n = 158) prioritized rapid speed of onset; and Group 4 (n = 129) favored health-care provider administration and durability of effectiveness. Conclusions: Speed of onset, durability of effectiveness, and mode of administration are key moderators of treatment preference among US adults with migraine. Certain segments of the migraine population prioritize specific treatment attributes over others, with intravenous infusion not considered a barrier in three of four identified segments. Clinicians can best help their patients find the right medication if they understand which medication attributes are most and least important to them.
KW - discrete choice experiment
KW - migraine
KW - patient preference
KW - preventive treatment
UR - http://www.scopus.com/inward/record.url?scp=85147594446&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85147594446&partnerID=8YFLogxK
U2 - 10.1111/head.14476
DO - 10.1111/head.14476
M3 - Article
AN - SCOPUS:85147594446
SN - 0017-8748
JO - Headache
JF - Headache
ER -